logo
One in seven Australians are on this medication and some have 'strange' symptoms coming off

One in seven Australians are on this medication and some have 'strange' symptoms coming off

SBS Australia2 days ago
Antidepressants are some of the most commonly prescribed medications globally and in Australia, but knowledge of how they work and how hard it is to come off them remains highly contested. Data from the Australian Institute of Health and Welfare shows nearly four million Australians — roughly one in seven — take antidepressants. A large systematic review of research into the process of withdrawing from the drugs was published this week, but it quickly faced backlash from some psychiatrists and experts. The authors found coming off antidepressants after short-term use was not associated with a "clinically significant" risk of withdrawal symptoms. However, long-term antidepressant use — that is longer than 12 months — is increasingly common and comes with a greater risk of harm. The review found withdrawal symptoms — such as dizziness, nausea, vertigo — occur in a minority of cases, but they are on average manageable and not severe, especially with proper clinical support.
The authors suggest that depression after stopping antidepressants is probably a relapse of the original mental health condition, as the results were similar among placebo groups.
The meta-analysis examined the findings of 50 randomised controlled trials, involving 17,828 participants. The review published in JAMA Psychiatry included 38 studies with an observation period longer than two weeks, the critical time frame during which withdrawal symptoms are expected to occur. The average age of the participants was 44, and 70 per cent were female. In Australia, women are prescribed antidepressants at 1.5 times the rate of men — a trend that's seen in other parts of the world. Some health professionals say the review provides useful insights, despite its limitations, while others have been highly critical. UK antidepressant researchers Mark Horowitz and Julie Moncrieff said the review "risks underestimating the potential harms to long-term antidepressant users by focusing on short-term, industry-funded studies." Several of the JAMA Psychiatry article's senior authors declared receiving payments from drug companies. Horowitz and Moncrieff argue that the article's "main analysis" is based on eleven trials, six of which looked at people who had taken antidepressants for eight weeks and four for 12 weeks.
"There is growing recognition that stopping antidepressants — especially after long-term use — can cause severe and sometimes debilitating withdrawal symptoms, and it is now acknowledged by the UK government as a public health issue," they wrote in The Conversation.
New resources have been developed to support people safely stopping the use of antidepressants over time usually months, through what's called a tapering plan.
The Maudsley Deprescribing Guidelines, published last year and co-authored by Horowitz, has been accepted by the Royal Australian College of General Practitioners as an Accepted Clinical Resource.
On again, off again antidepressant prescriptions Allied health professional Kizzy said she never wanted to be reliant on anti-depressants and has stopped taking them twice in the past. "I was initially quite resistant to any kind of medication, but I got to a point a couple of years ago ... where I was really struggling with suicidal thoughts and just being able to function and do things because of my mood, and all of these horrible feelings and thoughts I was having, and finally got convinced to try sertraline". She said she noticed the drug — a commonly prescribed antidepressant sometimes sold under the name Zoloft — was making her feel "numb". "My hope is that I can one day be not require antidepressants and still maintain this level of functioning and mental health," she said adding that her current medication "potentially affects" her liver.
The United States National Library of Medicine says liver abnormalities reportedly occur in around 1 per cent of people who take sertraline, "but elevations are usually modest and infrequently require dose modification or discontinuation".
Professor Paul Fitzgerald is the director of the School of Medicine and Psychology at Australian National University and a member of the Royal Australian and New Zealand College of Psychiatrists. He was not involved in the review. He said it's important to be aware of the more severe cases of side effects. "There are some unusual symptoms that patients experience. The most dramatic one the patients find quite disturbing is the phenomena that patients often talk about as brain zaps." "They get this very strange sensation of electrical zaps in their head or down their spinal cord, and if they haven't been warned about it, it can be quite distressing. It just seems strange." He said it's unclear from this latest review whether the symptoms recorded by researchers are a relapse of a previous mental health condition or withdrawal effects from discontinuing antidepressants. "What happens when somebody's stopping a medication and their underlying symptoms of their condition get worse? "In other words, start to experience more depression or more anxiety, and it can be really difficult to know under those circumstances.
"Are those symptoms that they're experiencing some sort of discontinuation or is it really just the symptoms of the illness coming back because the treatment's been withdrawn?"
Sonya Morrissey is the national GP adviser at Headspace, a platform supporting the mental health and wellbeing of younger people. She said that, in the past, patients weren't sufficiently warned about discontinuation symptoms of antidepressants. "It is something that we are, I think, recognising more and there's lots more research being done now, which is great, although there's not a significant amount of research yet in the cohort that we see, which is the 12 to 25 year olds," she said.
She said antidepressants are not their first line of treatment at Headspace, but will be used occasionally if needed.
LISTEN TO
SBS News
11/07/2025 08:17 English The Royal Australian College of General Practitioners' Western Australia vice-president, Dr Ramya Raman, said the recently published meta-analysis still provides useful insight for GPs but said more research on withdrawing from long-term anti-depressant use was needed. She also highlighted the importance of a good doctor-patient relationship when withdrawing from psychiatric medication. "When weaning off of the medication and there is a trusted relationship with the GP, and a regular follow-up with that doctor, the risk of having the discontinuation symptoms are less of a concern compared to when patients actually abruptly stop it. Kizzy also said finding a GP with an interest in mental health can make a big difference when navigating the use of antidepressants and the withdrawal process. "I think it's important to find a GP who has a genuine interest in that area rather than just going to your generic GP, finding a regular one who you know can rely on, who can really support you and speak to you in a way that you're going to feel respected and really understood. "And I think that's a really important kind of foundation support to have because once you have that, then you will feel safe enough to be checking in with them, sharing all your concerns, talking about coming off or going on or switching medications and still be okay through all of that." Readers seeking crisis support can ring Lifeline on 13 11 14 or text 0477 13 11 14, the Suicide Call Back Service on 1300 659 467 and Kids Helpline on 1800 55 1800 (for young people aged up to 25). More information and support with mental health is available at beyondblue.org.au and on 1300 22 4636.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Researchers map key north-south divide in Australia's orca population
Researchers map key north-south divide in Australia's orca population

ABC News

timean hour ago

  • ABC News

Researchers map key north-south divide in Australia's orca population

A new study has mapped the key habitats for Australia's orcas and thrown fresh weight behind the theory there are two distinct species in the nation's waters. Collating 1,310 sightings by whale watchers over four decades, researchers from Flinders University's Cetacean Ecology, Behaviour and Evolution Lab modelled orca species distributions and were able to pinpoint three key areas. In the south, the Bremer sub-basin off Western Australia's southern coast and the Bonney Upwelling off south-west Victoria were pinpointed as key locations. A population was identified in the warmer northern waters off Western Australia's Ningaloo Reef as well. Lead researcher and PhD candidate, Melissa Hutchings, said each region highlighted the varying environmental preferences of Australia's orca population. "Those off Ningaloo Reef, they're really drawn to those higher sea surface temperatures, strong productivity, and close-to-reef environments," Ms Hutchings said. "Whereas, in the south-west and south-east, they're preferring lower sea surface temperatures, stronger currents and a lot of upwelling as well." Ms Hutchings said their findings suggested there were two ecologically distinct types of killer whales in Australia. They are temperate or tropical, based on their environmental preferences. "As an apex predator, they will follow their prey aggregations, and then they will learn that is a predictable resource and will begin to specialise in that certain habitat," she said. Ms Hutchings said further research was needed to ensure adequate protection for the whales. "Commercial fishing, marine tourism, offshore drilling, chemical pollutants — all these things can have an impact, even on the ocean's top predator," she said. On Ningaloo Reef, the orca season is off to a later-than-usual start, with some people speculating the delay could be a result of warmer-than-usual water temperatures. The World Heritage site's winter feeding group was only spotted recently, hot on the trail of migrating humpback whales. John Totterdell, a field biologist at Cetacean Research Centre (CETREC) WA, said it was the thrill of the hunt that most distinguished tropical orcas like those at Ningaloo. "Killer whales in Ningaloo, for instance, have specialised in hunting humpback calves … they've got a strategy that's really precise," he said. "The other thing they've got [is] their distinct dialect. Dr Totterdell said skills like personality and familial roles were also handed down within the group, preparing younger whales for the challenges of life in the ocean. "It's pretty tough to make a living if you're a killer whale in the tropics," he said. "These humpbacks are only here for several months and some of the [orca] calves, in recent years, we have lost." The temperate orcas are found further south in the Bremer Bay region. "The orcas down in Bremer are offshore orcas living in a really deep water environment, so they're out over the continental shelf hunting anywhere between 700 and 2,000 metres," marine biologist Jennah Tucker said. "They are known to hunt cooperatively, in particular in Bremer, it's the largest known aggregation of orcas in the southern hemisphere. "In my time down there the most I've seen working together was between 70 and 80 orcas."

‘Anxious Mondays' linked to heart health risks
‘Anxious Mondays' linked to heart health risks

News.com.au

time2 hours ago

  • News.com.au

‘Anxious Mondays' linked to heart health risks

In news that should come as no surprise to anyone with a job, the Monday Blues aren't great for your health. Not to be confused with its older, scarier sibling, the Sunday Scaries, the Monday Blues describes that feeling of dread you have starting another working week. Not only do you have to return to work after a two-day break, but you're still five days away from your next respite. Now, a study has shown that feeling jittery as the week kicks off isn't just a mood – it leaves a biochemical footprint and drives long-term stress across the body. Monday scaries linked to higher stress hormones The study, published in the Journal of Affective Disorders, found that older adults who get that pang of anxiety on a Monday have significantly higher long-term stress hormone levels up to two months later. And here's the kicker. Even after you leave the workforce and retire, that almost automatic feeling of anxiousness on a Monday will still haunt you – showing a deep-rooted link between the start of the working week and dysregulation of the body's natural stress response system, which is a known driver of heart disease. Unlikely to be random, researchers say Researchers, including those from the University of Hong Kong, analysed data from more than 3500 adult participants of the English Longitudinal Study of Ageing (ELSA). Older adults in the study who experienced anxiety on Mondays showed nearly 25 per cent higher levels of the stress hormone cortisol in their hair samples. This suggests increased cumulative stress over two months compared to those reporting anxiety on different days. Alarmingly, Mondays are linked to a nearly 20 per cent spike in heart attacks. 'The increase in (cardiovascular) events on Mondays is unlikely to be a random phenomenon,' the researchers said. Scientists suspect that the body's hypothalamic-pituitary-adrenal (HPA) axis, which manages stress hormones such as cortisol, may be involved. Prolonged elevation of the HPA axis is associated with hypertension, insulin resistance, and immune system problems. 'This study found strong evidence for an association between reporting anxiety on Mondays and HPA-axis dysregulation,' the researchers explained. 'The anxious Monday association with HPA-axis dysregulation measured subsequently was evident among both working and nonworking older adults, with no reduction in the association among those not at work,' they wrote. 'This isn't about work' Previous studies indicated higher stress hormone levels during weekdays compared to weekends, but the newest research is the first to identify Mondays as particularly disruptive. 'For some older adults, the week's transition triggers a biological cascade that lingers for months. This isn't about work – it's about how deeply ingrained Mondays are in our stress physiology, even after careers end,' Tarani Chandola, one of the authors of the study, said.

Researchers develop injection in bid to replace multiple Parkinson's medications
Researchers develop injection in bid to replace multiple Parkinson's medications

ABC News

time4 hours ago

  • ABC News

Researchers develop injection in bid to replace multiple Parkinson's medications

Researchers have developed a new injection they hope will one day become a "game-changer" for people living with Parkinson's disease. Scientists from the University of South Australia have worked for more than two years to develop the formula, designed to replace the need for multiple daily oral medications. The dose combines two commonly used medications for Parkinson's — levodopa and carbidopa — into a single injection. The biodegradable solution is designed to be injected into a patient where it forms an implant under the skin and steadily releases the medication over seven days. "One injection will be good for one week as compared to a patient taking three or four tablets every day," Professor Sanjay Garg, from the University of South Australia's Centre for Pharmaceutical Innovation, said. Laboratory tests have so far confirmed the formula's effectiveness, but Professor Garg said the real test will be clinical trials in humans, which have yet to be undertaken. Professor Garg said the next phase will be to begin animal testing, which he hopes to start in six months, pending ethics approvals. "We will be applying these injections to animals and then assessing their blood concentrations to see how the drug release is happening," he said. He hopes the research could open up more possibilities to develop better ways to treat other chronic diseases. National peak body, Parkinson's Australia, estimates more than 150,000 Australians currently live with the disease, which progressively worsens over time and has no known cure, with treatment focusing on managing symptoms. University of South Australia PhD student, Deepa Nakmode, said the aim of creating an injectable drug was to simplify treatment for patients who currently take tablets between three to five times per day. Ms Nakmode said for elderly patients in particular, it can be difficult to remember to take each dose at the right time. "Even if they miss a single dose, they can't perform day to day activities normally," she said. Ms Nakmode said around 100 different combinations were tested before arriving at the final product, which has been filed for an Australian patent. "As a scientist you feel proud to come up with a product which is clinically needed, not just for the sake of research," she said. Parkinson's Australia CEO, Olivia Nassaris, has welcomed the findings, which she described as a "breakthrough" for patients. "There hasn't been much progress in Parkinson's medications for a number of years and the community is mostly on oral medications," Ms Nassaris said. "There is no such medication on the market which is the same as this." Former academic Peter Willis was diagnosed with the neurodegenerative condition 10 years ago, when he was in his 70s. "I was in the car and my hand shook. I thought, 'That's funny, I don't recall that happening [before]'," Mr Willis said. The 86-year-old takes oral medication four times a day in addition to other tablets for a heart condition — but he admits he sometimes forgets. He said a weekly injection would be easier to manage. "Having to remember four every day is a pain in the arse," he said. Mr Willis said he noticed a deterioration in his symptoms if he was not precise in the timing of taking his daily medications. "If you don't take the tablet on time, you discover you can't walk," he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store